soul trial oral semaglutide cardiovascular outcomes 2024 results mace reduction New Science Suggests Improves CV Beyond Weight Loss Oral semaglutide found to lower
Description
Diarrhea can be mild or more intense and may come and go throughout treatment
The study included patients who were newly prescribed semaglutide or other non-GLP-1 receptor agonist medications for obesity or diabetes from June 2021 to December 2022
For most patients, the benefits of improved blood sugar control and weight loss likely outweigh the inconvenience of feeling cold
& Deng, N
Clinical trials demonstrate significantly greater weight loss with GLP-1 drugs compared to bupropion alone
LDL cholesterol drops by 12% while triglycerides fall by 28% over 48 weeks of treatment
